Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due to age and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Exp Hematol Oncol
Autores principales: Jilg, Stefanie, Hauch, Richard T., Kauschinger, Johanna, Buschhorn, Lars, Odinius, Timo O., Dill, Veronika, Müller-Thomas, Catharina, Herold, Tobias, Prodinger, Peter M., Schmidt, Burkhard, Hempel, Dirk, Bassermann, Florian, Peschel, Christian, Götze, Katharina S., Höckendorf, Ulrike, Haferlach, Torsten, Jost, Philipp J.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2019
Materias:
Rapid Communication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469098/
https://ncbi.nlm.nih.gov/pubmed/31016067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0133-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares